Zepbound Weekly Shot for Weight and Sleep Apnea

People hear “tirzepatide shot” and think one product. Regulators do not. Mounjaro is the brand many countries use for type 2 diabetes (and, in some places, for weight management under the same brand name). Zepbound is the weight / OSA brand used in the United States and Canada. Same active ingredient. Different carton, different labelled population, different pharmacy path. Mixing them in your head — or stacking them — is how people get the wrong script.

This episode is Zepbound for weight and OSA (and the international brand-split map). Episode 1 covered injectable Wegovy. Episode 3 covers oral Wegovy vs Foundayo. The live Mounjaro CV (tirzepatide) piece is a type 2 diabetes heart-protection US door — cross-link only; this episode does not rewrite it. Compounded tirzepatide is not an Access Level door.

Where this is taking place

Commercial path: a prescriber writes the local labelled carton — Zepbound in the US/Canada for weight and/or OSA where the label fits, or Mounjaro for weight management where that is the local brand — a pharmacy dispenses a real Eli Lilly carton, and you inject once weekly under the skin (abdomen, thigh, or upper arm) with a reduced-calorie diet and more activity. This is not a trial slot and not a compounding bench.

Key evidence programmes that sit under the labels (historical — not open enrolment doors for a first commercial script):

• Weight (adults): SURMOUNT programme (e.g. NCT04184622 SURMOUNT-1 and related SURMOUNT trials named on the current USPI / Product Monograph).
• OSA in adults with obesity: SURMOUNT-OSA master protocol — NCT05412004 — two 52-week randomized trials (PAP-unable/unwilling and PAP users); primary publication in NEJM (DOI 10.1056/NEJMoa2404881).

Series map (brief, not rehash): Episode 1 covers injectable Wegovy (semaglutide weight / heart / MASH doors). Mounjaro CV (tirzepatide) is the separate US type 2 diabetes heart-protection door — live single, not a rewrite. Foundayo / oral Wegovy wait for Episode 3.

Approval matrix (weight + OSA — brand split)

Use the label of the country that will prescribe. A US Zepbound OSA line does not travel onto an EU Mounjaro pack that only carries weight management with OSA as a comorbidity example.

Access by country

• United States: Ask a clinician who manages obesity and/or sleep medicine about labelled Zepbound. FDA doors above. Start 2.5 mg once weekly for 4 weeks (initiation only — not a maintenance dose); escalate by 2.5 mg after ≥4 weeks. Maintenance for weight: 5, 10, or 15 mg; for OSA: 10 or 15 mg; maximum 15 mg weekly. Do not combine with Mounjaro or any other tirzepatide product, or with any GLP-1 receptor agonist. Prior authorization is common. No public-funding win is claimed here. Eli Lilly adverse events: 1-800-LillyRx (1-800-545-5979); FDA MedWatch 1-800-FDA-1088. Pregnancy registry: 1-844-524-0039 / pregnancyregistry.lilly.com/zepbound.

• Canada (zoom, not a different Access Level): Health Canada–authorized Zepbound for chronic weight management (adults) and for moderate-to-severe OSA in adults with obesity (BMI ≥30). Product Monograph 11 Jun 2026 explicitly warns against coadministration with Mounjaro or other GLP-1 RAs. A Notice of Compliance is not a provincial formulary listing. Public plan / NIHB / RAMQ listing status for these doors: unknown / not confirmed on this page — no listing win is claimed here. Private insurance and cash still require a labelled Zepbound prescription. SAP is the wrong door for a marketed product. Do not mail-order a US pen as a Canadian care plan. Zepbound is not a replacement for PAP when the clinician says PAP is still needed.

• United Kingdom: Local brand is Mounjaro, not Zepbound. MHRA-labelled for adult weight management (BMI criteria above; OSA appears as a weight-related comorbidity example, with SURMOUNT-OSA data in SmPC 5.1). Ask the NHS/specialist weight-management team what is commissioned under NICE TA1026 and NHS England’s phased cohorts — the funded door is narrower than the full marketing authorisation. Authorized ≠ NHS funded for every adult who meets the SmPC. Yellow Card for suspected side effects.

• EU/EEA: Commission-authorised Mounjaro weight-management door (adults). OSA is an example comorbidity in the indication wording; EMA concluded a separate OSA indication was not needed. National reimbursement lags country by country — unknown here unless a country file is opened. Do not import a US Zepbound carton as an EU care plan.

• Australia: ARTG-registered Mounjaro for chronic weight management (2024) and for moderate-to-severe OSA in adults with obesity (2025). Specialist/GP path per local rules. PBS unknown / not confirmed on this page.

• If your regulator has not authorised the door you need: do not import on your own. Ask a local clinician about legal special-access / named-patient rules only if those programs apply — or wait for a local label.

What it actually is

Zepbound (US/Canada) is tirzepatide, a dual GIP and GLP-1 receptor agonist, in a once-weekly subcutaneous pen, vial, or KwikPen. It is used with diet and activity.

It is not:

• Mounjaro as the US/Canada weight/OSA carton (different brand door there — and do not stack the two)
• The live Mounjaro CV diabetes heart-protection door (cross-link only)
• Wegovy / Ozempic / Rybelsus (semaglutide — Episode 1 / diabetes brands)
• Foundayo / oral Wegovy (Episode 3)
• A general sleep-apnea medicine for people without obesity
• A guaranteed replacement for PAP / CPAP
• Compounded tirzepatide
• Public coverage just because a regulator said yes
• A pediatric weight door (US and Canadian labels: pediatric use not established / not authorized)

US / Canada escalation (adults): weeks 1–4: 2.5 mg; then increase by 2.5 mg after ≥4 weeks on the current dose until the recommended maintenance dose. Weight maintenance: 5, 10, or 15 mg. OSA maintenance: 10 or 15 mg. Maximum: 15 mg weekly. Missed dose (USPI): take as soon as possible within 4 days (96 hours); if more than 4 days have passed, skip and resume on the next scheduled day. Day-of-week can change if ≥ 3 days (72 hours) between doses.

What the trials showed (plain numbers)

Weight — adults (SURMOUNT-1 pattern, US/HC labels): At ~72 weeks in adults with obesity or overweight + comorbidity without diabetes, people on Zepbound lost on the order of ~15% to ~21% of body weight depending on dose (5 / 10 / 15 mg) vs low single-digit % on placebo (exact tables live on the USPI / Product Monograph). Most common reason people stop: stomach side effects during escalation.

OSA — SURMOUNT-OSA (Studies 5 and 6 on the USPI; NCT05412004): In ~469 adults with moderate-to-severe OSA and obesity (no type 2 diabetes in the pivotal design), weekly Zepbound at maximum tolerated 10 or 15 mg for 52 weeks cut the apnea-hypopnea index (AHI) by about 20–24 events/hour more than placebo (Study 5 / Study 6 patterns on the USPI). More people on drug reached remission or mild non-symptomatic OSA. Body weight also fell on the order of ~16–18% relative difference vs placebo. Trials measured AHI and related outcomes over 52 weeks — they did not license a DIY PAP quit plan. Decisions to start, continue, or change PAP stay with the clinician (Canadian monograph says this explicitly).

Safety a household should actually watch

Boxed / serious warning (US / Canada class language): Risk of thyroid C-cell tumours in rodents. Do not use if you or your family have medullary thyroid cancer (MTC) or MEN2.

Common: nausea, diarrhea, vomiting, constipation, abdominal pain, dyspepsia, injection-site reactions, fatigue, burping, hair loss, reflux — especially while doses climb.

Watch for and call urgently: severe persistent abdominal pain (pancreatitis), gallbladder pain, signs of severe allergic reaction, symptoms of low blood sugar if you also take insulin or a sulfonylurea, dehydration from vomiting/diarrhea (kidney injury risk), vision changes if you have diabetes and retinopathy history.

Other USPI / monograph watchpoints: delayed stomach emptying — tell surgeons/anesthesia teams before procedures; do not share multi-dose pens/KwikPens between people; not recommended in severe gastroparesis.

Pregnancy: May cause fetal harm. Discontinue when pregnancy is recognized. US label: plan pregnancy carefully given long half-life; oral contraceptive efficacy may drop after start and each escalation — switch to non-oral or add a barrier method for 4 weeks after initiation and after each dose increase (USPI). Canada: contraindicated in pregnancy per Product Monograph.

Teens: Not a paediatric door on the US or Canadian Zepbound labels used here. (EU/UK Mounjaro has separate paediatric diabetes wording ages 10+ — that is not this episode’s weight/OSA door.)

Access: what you can actually do

1. Name the brand on the script: Zepbound (US/Canada) — not “just tirzepatide”

If the clinic says “I’ll just write tirzepatide,” ask which labelled brand and indication they mean. In the US and Canada, the weight/OSA carton is Zepbound. Mounjaro is a different branded conversation (diabetes / local weight brand abroad) — and stacking both is not recommended on the label.

2. Who to see

A clinician who already manages obesity and/or sleep apnea: primary care, obesity medicine, endocrinology, or sleep medicine. Bring: BMI, sleep-study / AHI results if you have them, PAP use history, weight-related conditions, full med list (especially other GLP-1s, insulin, sulfonylureas, other tirzepatide products), gallbladder history, pregnancy plans, and prior weight attempts.

3. Script for the visit

I am asking about the labelled weight / OSA tirzepatide door for this country — in the US and Canada that means Zepbound, not compounded tirzepatide and not stacking Mounjaro. On the US label, Zepbound covers chronic weight management in adults with obesity or overweight plus a weight-related condition, and moderate-to-severe OSA in adults with obesity. Health Canada authorizes the same two doors on the Zepbound Product Monograph, with an explicit warning not to combine with Mounjaro or other GLP-1 medicines. I want to know which door I fit, whether you will prescribe the correct local carton, whether PAP still needs to continue, and what the realistic payment path is — private insurance, manufacturer support if any, or cash. I understand authorized is not funded, and this is not a general sleep-apnea drug without obesity.

Ask:

• Which labelled indication applies to me here?
• Am I outside the label (under 18 on Zepbound; BMI too low for the OSA door; MEN2/MTC; pregnancy)?
• Escalation plan and what to do if I miss a week?
• How do we handle insurance prior authorization language (Zepbound / tirzepatide / weight or OSA)?
• Do I still need PAP, and who decides changes?
• Surgery or procedures coming up?

4. Payment honesty

Authorized ≠ funded. US commercial prior auth is common. Canadian public listing for these doors is not confirmed on this page — do not treat an NOC as a formulary win. UK: NICE/NHS England fund Mounjaro for weight under phased, narrower cohorts than the full SmPC. Australia PBS: unknown / not confirmed. Episode 4 covers reimbursement process across the series doors.

5. Compounded products are not this door

If a spa, med-spa, or online seller offers “tirzepatide” without a labelled Zepbound (or local Mounjaro) carton, that is not the Access Level path this episode maps.

6. Clinical trials

SURMOUNT and SURMOUNT-OSA support labels; they are not a 2026 walk-in enrolment path for a first commercial pen. Search ClinicalTrials.gov with your clinician only if you need a research door your local label does not cover.

7. If you are not a candidate

Under 18 on the Zepbound labels used here; personal/family MTC or MEN2; pregnancy; OSA without obesity when the label requires obesity; or a different molecule already labelled for your situation (see Episode 1 Wegovy / Episode 3 orals). Ask for the labelled alternative — do not substitute brands in your head, and do not stack tirzepatide products.

---

Bottom line

Zepbound is a real, labelled, once-weekly tirzepatide shot with two North American doors: chronic weight management in adults, and moderate-to-severe OSA in adults with obesity. In the EU, UK, and Australia the same molecule usually arrives as Mounjaro, with OSA either as a comorbidity example, trial data in the SmPC, or (Australia) a separate registered OSA line — never invent a local “Zepbound” carton. It is not the live Mounjaro diabetes CV article. It is not a sleep-apnea cure or an automatic PAP replacement. It is not funded just because it is authorized. Ask for the correct local brand that matches your country’s label — then fight the payment step with eyes open.

---